Targeted beta therapy of human prostate cancer in vivo with Lu-177 labelled MIL-38 antibody against glypican-1 (GPC-1)

Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Huston, Chelsea Stewart, Kamil Sokolowski, Varinder Jeet, Sandra Wissmueller, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson, Pamela J. Russell

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Article number078
Pages (from-to)34-35
Number of pages2
JournalBJU International
Volume122
Issue numberS2
Publication statusPublished - Aug 2018
Externally publishedYes
Event19th Asia-Pacific Prostate Cancer Conference - Brisbane, Australia
Duration: 22 Aug 201825 Aug 2018

Cite this

Yeh, M-C., Tse, B. W. C., Fletcher, N. L., Huston, Z. H., Stewart, C., Sokolowski, K., ... Russell, P. J. (2018). Targeted beta therapy of human prostate cancer in vivo with Lu-177 labelled MIL-38 antibody against glypican-1 (GPC-1). BJU International, 122(S2), 34-35. [078].